MARKET

PCRX

PCRX

Pacira Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

61.41
-2.17
-3.41%
After Hours: 61.50 +0.09 +0.15% 16:26 05/18 EDT
OPEN
62.59
PREV CLOSE
63.58
HIGH
63.66
LOW
60.67
VOLUME
406.15K
TURNOVER
2.38M
52 WEEK HIGH
82.16
52 WEEK LOW
45.05
MARKET CAP
2.79B
P/E (TTM)
72.94
1D
5D
1M
3M
1Y
5Y
Paulson & Co. adds Agnico Eagle Mines, slashes stake in BP, expands position in Bausch Health
John Paulson's fund, Paulson & Co. reported its 13F filing for Q2 wherein it added Agnico Eagle Mines (AEM) with 10.3M shares and SPDR Gold Trust ETF (GLD) with 10M
Seekingalpha · 1d ago
Pacira BioSciences Posts Higher Exparel, Lower Iovera Sales in April
MT Newswires · 6d ago
Here's Why Pacira (PCRX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks · 05/10 13:45
Pacira BioSciences to Present at Two Healthcare Conferences in May
TAMPA, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: 2022 RBC Capital Markets Global Healthcare Conferenc...
GlobeNewswire · 05/10 12:00
Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y
Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.
Zacks · 05/05 15:26
--RBC Capital Adjusts Pacira BioSciences' Price Target to $81 From $85, Maintains Outperform Rating
MT Newswires · 05/05 09:31
Pacira (PCRX) Q1 Earnings Miss Estimates
Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 13:15
Pacira BioSciences: Q1 Earnings Insights
  Pacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 12:26
More
No Data
Learn about the latest financial forecast of PCRX. Analyze the recent business situations of Pacira Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

21.43%Strong Buy
57.14%Buy
21.43%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PCRX stock price target is 78.71 with a high estimate of 94.00 and a low estimate of 54.00.
High94.00
Average78.71
Low54.00
Current 61.41
EPS
Actual
Estimate
0.240.480.730.97
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 399
Institutional Holdings: 54.39M
% Owned: 119.71%
Shares Outstanding: 45.44M
TypeInstitutionsShares
Increased
104
3.48M
New
45
661.10K
Decreased
81
2.42M
Sold Out
25
376.37K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.80%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Chairman/Chief Executive Officer/Director
David Stack
Chief Financial Officer
Charles Reinhart
Corporate Executive
Max Reinhardt
Chief Operating Officer
Daryl Gaugler
Chief Administrative Officer/Secretary
Kristen Williams
Chief Compliance Officer
Anthony Molloy
Other
Charles Laranjeira
Other
Dennis McLoughlin
Other
Jonathan Slonin
Other
Roy Winston
Lead Director/Independent Director
Paul Hastings
Director
Christopher Christie
Independent Director
Laura Brege
Independent Director
Mark Froimson
Independent Director
Yvonne Greenstreet
Independent Director
Mark Kronenfeld
Independent Director
Gary Pace
Independent Director
Andreas Wicki
No Data
No Data
About PCRX
Pacira BioSciences, Inc. is the holding company of Pacira Pharmaceuticals, Inc. The Company is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Webull offers kinds of Pacira Biosciences Inc stock information, including NASDAQ:PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.